Literature DB >> 27007263

Optic pathway glioma in children: 10 years of experience in a single institution.

Dimitrios Doganis1, Apostolos Pourtsidis1, Kleonikos Tsakiris2, Margarita Baka1, Agathi Kouri2, Despina Bouhoutsou1, Maria Varvoutsi1, Marina Servitzoglou1, Helen Dana1, Helen Kosmidis1.   

Abstract

Optic pathway glioma (OPG) is a rare brain tumor that occurs more commonly during early childhood and is frequently associated with neurofibromatosis type 1 (NF1). In this study, our aim was to describe the characteristics, management, and outcome of patients with OPG. We retrospectively analyzed the clinical charts of all children diagnosed with OPG at our institution from 2003 to 2013. Twenty children (11 boys and 9 girls, median age: 5 and 3/12 years; NF1: 15/20) were diagnosed with OPG. The diagnosis was based on magnetic resonance imaging (MRI) findings. A biopsy was useful in 3 patients. The main reason for seeking medical advice was decreased vision (7/20 patients), whereas in 10/20 patients, the diagnosis was established during the routine follow-up for their NF1. Fifteen patients demonstrated MRI findings of optic nerve involvement and/or chiasmal tumor, whereas in 5 children, postchiasmal structures were also involved. Sixteen patients (16/20) received carboplatin-based regimens, whereas 4/20 patients were only under close observation. Six patients showed deterioration of visual acuity and/or imaging findings at the end of treatment and/or during their follow-up. Three of them (3/6) underwent tumor resection, whereas 1 (1/6) received radiation treatment. None of our patients had total blindness from both eyes. Half of our patients were diagnosed during follow-up for their NF1, the incidence of which was high in our group. Our data suggest that chemotherapy helps in the preservation of vision in the majority of children.

Entities:  

Keywords:  Children; glioma; optic pathway

Mesh:

Year:  2016        PMID: 27007263     DOI: 10.3109/08880018.2016.1155101

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  4 in total

1.  Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.

Authors:  Eva Trevisson; Matteo Cassina; Enrico Opocher; Virginia Vicenzi; Marta Lucchetta; Raffaele Parrozzani; Giacomo Miglionico; Rodica Mardari; Elisabetta Viscardi; Edoardo Midena; Maurizio Clementi
Journal:  J Neurooncol       Date:  2017-06-02       Impact factor: 4.130

Review 2.  Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis.

Authors:  Omid Yousefi; Pouria Azami; Mohammadmahdi Sabahi; Rocco Dabecco; Badih Adada; Hamid Borghei-Razavi
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

3.  Nonoptic pathway tumors in children with neurofibromatosis type 1.

Authors:  Jasia Mahdi; Manu S Goyal; Jennifer Griffith; Stephanie M Morris; David H Gutmann
Journal:  Neurology       Date:  2020-04-16       Impact factor: 9.910

4.  Comparison of two surgical methods for the treatment of optic pathway gliomas in the intraorbital segment: an analysis of long-term clinical follow-up, which evaluates the surgical outcomes.

Authors:  Peng Yang; Hao-Cheng Liu; E Qiu; Wei Wang; Jia-Liang Zhang; Li-Bin Jiang; Jun Kang
Journal:  Transl Pediatr       Date:  2021-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.